Navigation Links
Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer
Date:11/5/2011

Carcinoma: Final Data."

A randomized, placebo-controlled Phase 2b clinical trial of JX-594 in patients with hepatocellular carcinoma (HCC) having failed sorafenib (Nexavar®) treatment was recently initiated; this trial (TRAVERSE), conducted globally with Jennerex's partners, is evaluating survival in advanced HCC patients who have either progressed or exhibited intolerance after treatment with sorafenib, the current standard of care.

"These data showing an improvement in overall survival are very encouraging—particularly when coupled with the favorable tolerability profile of JX-594 experienced in this and prior clinical trials. Another therapeutic option to treat patients with HCC, the third leading cause of cancer death globally, is urgently needed," stated Dr. Reid, a clinical investigator on the HEP007 clinical trial.

"The strength of these data—showing a statistically significant benefit in overall survival—gives us great confidence in the potential of JX-594 to benefit patients with liver and other types of cancer world-wide," stated David H. Kirn, M.D., president and chief medical officer of Jennerex.  "Based on these clinical data, and clinical data we've previously published, we are accelerating the development of JX-594. Together with our partners, we're initiating a more expansive late-stage TRAVERSE clinical trial of JX-594 in HCC, and we're moving into Phase 1/2 trials in additional cancer types, including ras mutant and Erbitux-refractory colorectal cancer."

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the b
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... MILWAUKEE, Wis. (PRWEB) , ... July 29, 2015 ... ... facility identification solutions, today announced its GHS Label Guide . To align ... Harmonized System (GHS), this guide includes explanations of label components, an example of ...
(Date:7/29/2015)...  Therapath Neuropathology ( www.Therapath.com ), a leader ... and Military Medical centers both domestically and worldwide.  ... Sweat Gland Nerve Fiber Density (SGNFD) for the ... Demonstration of a reduction in ... skin biopsy is a highly sensitive and specific ...
(Date:7/29/2015)... -- Indivior PLC (LON: INDV) today announced that the New ... and received Priority Review by the U.S. Food and ... This naloxone nasal spray comes as a pre-filled device ... the nasal mucosa. 1 The device has been ... better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... announce that the final design specifications of its ... for industrial and regulatory testing will now be ... mark clearance to market the injector in ... (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  The RCI-02 ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... MOUNTAIN VIEW, Calif., May 12 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... quarter ended March 31, 2008 and provided an update ... loss for the 2008,first fiscal quarter, as reported in ... (GAAP), was $14.6 million, compared,to a net loss of ...
... IDIX ) announced today that Idenix management,will present ... Annual Global,Healthcare Conference on Tuesday, May 20, 2008 at ... Monte Carlo, Monaco., The live and archived webcast ... Events" in the Idenix Investor Center at, http://www.idenix.com . ...
... N.J., May 12 Synvista Therapeutics,Inc. (Amex: SYI ) ... Officer of Synvista will present at the upcoming Rodman,& Renshaw ... 12:10 p.m. CEST (6:10 a.m. EDT). The event will be ... Hotel in Monte Carlo., Dr. Berkowitz will discuss the ...
Cached Biology Technology:Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 2Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 3Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 4Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 5Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 6Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 7Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 8Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 9Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 10Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference 2Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference 3
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... 2009 A canine chromosome 7 locus that confers ... identified through a collaboration between the Behavior Service at ... Medical Genetics at the University of Massachusetts Medical School ... Technology. The findings are published in the January 2010 ...
... lll. Researchers report that Helicobacter pylori , ... environment of the human stomach, directly activates an enzyme ... types of cancer, including gastric cancer. Chronic infection ... factor for several forms of gastric cancer, but researchers ...
... scientific conference has provided new evidence for the ... of spectacular marine life, including deadly jellyfish, basking ... ,South West Marine Ecosystems, meeting, held in Plymouth ... the scientific, conservation, fishing and eco-tourism sectors. The ...
Cached Biology News:Canine compulsive disorder gene identified in dogs 2Canine compulsive disorder gene identified in dogs 3Team finds link between stomach-cancer bug and cancer-promoting factor 2Team finds link between stomach-cancer bug and cancer-promoting factor 3Conference highlights impact of unsettled summer weather on UK marine life 2
... enzyme mix (Thermoprime Plus DNA Polymerase with ... four times higher fidelity than standard Taq ... Taq DNA polymerase, Amplifies DNA templates >20kb, ... PCR, PCR for cloning and mutagenesis We ...
RNA oligomers from 10 to 50 bases purified by PAGE and MS-checked. RNAs are supplied dried and fully deprotected....
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. The ... as a one-cabinet model, allowing ...
... is a modified cap analog in which ... is replaced with OCH3. Because of this ... transcription with the remaining hydroxyl group thus ... As a result, unlike transcripts synthesized with ...
Biology Products: